Development of dengue virus vaccine components

摘要

The invention is related to a dengue virus or chimeric dengue virus that contains a mutation in the 3′untranslated region (3′-UTR) comprising a Δ30 mutation that removes the TL-2 homologous structure in each of the dengue virus serotypes 1, 2, 3, and 4, and nucleotides additional to the Δ30 mutation deleted from the 3′-UTR that removes sequence in the 5′direction as far as the 5′boundary of the TL-3 homologous structure in each of the dengue virus serotypes 1, 2, 3, and 4, or a replacement of the 3′-UTR of a dengue virus of a first serotype with the 3′-UTR of a dengue virus of a second serotype, optionally containing the Δ30 mutation and nucleotides additional to the Δ30 mutation deleted from the 3′-UTR; and immunogenic compositions, methods of inducing an immune response, and methods of producing a dengue virus or chimeric dengue virus.

主权项

1. A nucleic acid encoding a dengue virus or chimeric dengue virus comprising a first 3′-UTR of a first dengue virus serotype which has been replaced with a corresponding second 3′-UTR of a second dengue virus serotype, optionally wherein the second 3′UTR contains the Δ30mutation and nucleotides additional to the Δ30mutation deleted from the first 3′-UTR, and wherein the first or second dengue virus serotype is dengue virus serotype 1, 2, 3 or 4, and wherein the first and the second dengue viruses are different serotypes.